Astellas XenoPort and Pharma submit NDA in Japan for PMDA approval Astellas Pharma Inc.

Astellas XenoPort and Pharma submit NDA in Japan for PMDA approval Astellas Pharma Inc. And XenoPort, Inc. today announced that a new drug program has been filed with the Pharmaceuticals and Medical Device Company in Japan for ASP8825 , known as XP13512 also, as a potential treatment for restless legs syndrome . The info supporting basic safety and efficacy in the NDA filing originates from the successful Phase 2 research in RLS sufferers and long-term safety study executed by Astellas in Japan and the RLS scientific program conducted by XenoPort in the usa.Related StoriesHealthcare technology sociable event of the entire year opens entriesSurgical startup seeks financing to build virtual reality schooling libraryGenetic carrier screening: an interview with Don Hardison, CEO of Good Start Genetics Calamar contributed the properties to the joint venture in exchange for its 25 percent ownership interest and Treatment funded its 75 percent portion of its equity expenditure with cash readily available.3 million, provided by Liberty Bank. Salvatore V. Riso, Jr. , President and Chief Executive Officer of Care, stated, Care is quite pleased to partner with Calamar who has generated itself as providing high quality, inexpensive, communities to seniors.